Publications by authors named "Corey Carter"

Claim this Profile
M
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel, Corey Carter

Cancer Cell· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of safety and efficacy of atezolizumab therapy across indications.
Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde, Corey Carter

J Immunother Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
Daniel R Zollinger, Elizabeth Rivers, Alexander Fine, Yanmei Huang, Joseph Son, Corey Carter

PLoS One· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Thomas Powles, Zoe June Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Corey Carter

Eur Urol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Thomas Powles, Amanda Young, Halla Nimeiri, Russell W Madison, Alexander Fine, Corey Carter

Front Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Brant A Inman, Noah M Hahn, Kelly Stratton, Ryan Kopp, Alex Sankin, Corey Carter

Eur Urol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast neutron mutagenesis in soybean enriches for small indels and creates frameshift mutations.
Skylar R Wyant, M Fernanda Rodriguez, Corey K Carter, Wayne A Parrott, Scott A Jackson

G3 (Bethesda)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study of survival among small cell lung cancer patients in the U.S. military health system and those in the surveillance, epidemiology, and end results (SEER) program.
Jie Lin, Christine Kamamia, Derek W Brown, Stephanie Shao, Katherine A McGlynn, Corey A Carter

Ann Epidemiol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Thomas Powles, Zoe June Assaf, Nicole Davarpanah, Romain Banchereau, Bernadett E Szabados, Corey Carter

Nature· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Just eat it: A review of CD47 and SIRP-α antagonism.
Bryan Oronsky, Corey Carter, Tony Reid, Franck Brinkhaus, Susan J Knox

Semin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix.
Scott Caroen, Bryan Oronsky, Corey Carter, Michelle Lybeck, Arnold Oronsky

Expert Opin Drug Deliv· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-beta: a master immune regulator.
Christopher Larson, Bryan Oronsky, Corey A Carter, Arnold Oronsky, Susan J Knox

Expert Opin Ther Targets· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".
Bryan Oronsky, Corey A Carter, Scott Caroen, Curtis Scribner, Arnold Oronsky

Oncoimmunology· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients.
Michael Bouvet, Tony R Reid, Chris Larson, Bryan Oronsky, Corey Carter

Oxf Med Case Reports· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Multiparent Population for Genetic Mapping and Allele Discovery in Six-Row Barley.
Alex Hemshrot, Ana M Poets, Priyanka Tyagi, Li Lei, Corey K Carter

Genetics· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Environmental Association Identifies Candidates for Tolerance to Low Temperature and Drought.
Li Lei, Ana M Poets, Chaochih Liu, Skylar R Wyant, Paul J Hoffman, Corey K Carter

G3 (Bethesda)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Bryan Oronsky, Tony R Reid, Christopher Larson, Scott Caroen, Mary Quinn, Corey A Carter

Future Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Bryan Oronsky, Eilleen S Y Ao-Ieong, Ozlem Yalcin, Corey A Carter, Pedro Cabrales

Mol Pharm· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Nitin Roper, Shaojian Gao, Tapan K Maity, A Rouf Banday, Xu Zhang, Corey A Carter

Cell Rep· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer.
Bryan Oronsky, Chris Larson, Tony R Reid, Corey A Carter

J Investig Med High Impact Case Rep· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs).
Christopher Larson, Bryan Oronsky, Gina Varner, Scott Caroen, Erica Burbano, Corey A Carter

Oncoimmunology· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER Population.
Jie Lin, Christine Kamamia, Derek Brown, Stephanie Shao, Katherine A McGlynn, Corey A Carter

Cancer Epidemiol Biomarkers Prev· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.
Bryan Oronsky, Sharad Goyal, Michelle M Kim, Pedro Cabrales, Michelle Lybeck, Corey Carter

Transl Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.
Bryan Oronsky, Tony R Reid, Arnold Oronsky, Scott Caroen, Corey A Carter

Oncotarget· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.
Bryan Oronsky, Patrick Ma, Tony R Reid, Pedro Cabrales, Michelle Lybeck, Corey A Carter

Neoplasia· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis